Research programme: anti-CD19 antibodies - Bristol-Myers Squibb/Genmab
Latest Information Update: 28 Jul 2019
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Genmab
- Class Antibodies
- Mechanism of Action CD19 antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies